271 related articles for article (PubMed ID: 29458332)
21. Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition.
Martin-Morales L; Rofes P; Diaz-Rubio E; Llovet P; Lorca V; Bando I; Perez-Segura P; de la Hoya M; Garre P; Garcia-Barberan V; Caldes T
PLoS One; 2018; 13(9):e0203885. PubMed ID: 30256826
[TBL] [Abstract][Full Text] [Related]
22. [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].
Schneider R; Schneider C; Büttner R; Reinacher-Schick A; Tannapfel A; Fürst A; Rüschoff J; Jakobeit C; Royer-Pokora B; Möslein G
Zentralbl Chir; 2015 Dec; 140(6):591-9. PubMed ID: 25372301
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
Maccaroni E; Bracci R; Giampieri R; Bianchi F; Belvederesi L; Brugiati C; Pagliaretta S; Del Prete M; Scartozzi M; Cascinu S
Oncotarget; 2015 Nov; 6(36):38737-48. PubMed ID: 26485756
[TBL] [Abstract][Full Text] [Related]
24. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.
Bonis PA; Trikalinos TA; Chung M; Chew P; Ip S; DeVine DA; Lau J
Evid Rep Technol Assess (Full Rep); 2007 May; (150):1-180. PubMed ID: 17764220
[TBL] [Abstract][Full Text] [Related]
25. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
[TBL] [Abstract][Full Text] [Related]
26. Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Vasen HF
Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():113-26. PubMed ID: 18081655
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.
Siraj AK; Prabhakaran S; Bavi P; Bu R; Beg S; Hazmi MA; Al-Rasheed M; Al-Assiri M; Sairafi R; Al-Dayel F; Al-Sanea N; Uddin S; Al-Kuraya KS
Cancer; 2015 Jun; 121(11):1762-71. PubMed ID: 25712738
[TBL] [Abstract][Full Text] [Related]
29. Detection of germline variants with pathogenic potential in 48 patients with familial colorectal cancer by using whole exome sequencing.
Singh AK; Talseth-Palmer B; Xavier A; Scott RJ; Drabløs F; Sjursen W
BMC Med Genomics; 2023 Jun; 16(1):126. PubMed ID: 37296477
[TBL] [Abstract][Full Text] [Related]
30. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X.
Lindor NM; Rabe K; Petersen GM; Haile R; Casey G; Baron J; Gallinger S; Bapat B; Aronson M; Hopper J; Jass J; LeMarchand L; Grove J; Potter J; Newcomb P; Terdiman JP; Conrad P; Moslein G; Goldberg R; Ziogas A; Anton-Culver H; de Andrade M; Siegmund K; Thibodeau SN; Boardman LA; Seminara D
JAMA; 2005 Apr; 293(16):1979-85. PubMed ID: 15855431
[TBL] [Abstract][Full Text] [Related]
31. Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.
Houlleberghs H; Dekker M; Lantermans H; Kleinendorst R; Dubbink HJ; Hofstra RM; Verhoef S; Te Riele H
Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4128-33. PubMed ID: 26951660
[TBL] [Abstract][Full Text] [Related]
32. Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future.
Rasmussen LJ; Heinen CD; Royer-Pokora B; Drost M; Tavtigian S; Hofstra RM; de Wind N
Hum Mutat; 2012 Dec; 33(12):1617-25. PubMed ID: 22833534
[TBL] [Abstract][Full Text] [Related]
33. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers.
Kang SY; Park CK; Chang DK; Kim JW; Son HJ; Cho YB; Yun SH; Kim HC; Kwon M; Kim KM
Int J Cancer; 2015 Apr; 136(7):1568-78. PubMed ID: 25110875
[TBL] [Abstract][Full Text] [Related]
34. Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants.
Borràs E; Pineda M; Cadiñanos J; Del Valle J; Brieger A; Hinrichsen I; Cabanillas R; Navarro M; Brunet J; Sanjuan X; Musulen E; van der Klift H; Lázaro C; Plotz G; Blanco I; Capellá G
J Med Genet; 2013 Aug; 50(8):552-63. PubMed ID: 23709753
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
[TBL] [Abstract][Full Text] [Related]
36. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy.
Pastorino R; Basile M; Tognetto A; Di Marco M; Grossi A; Lucci-Cordisco E; Scaldaferri F; De Censi A; Federici A; Villari P; Genuardi M; Ricciardi W; Boccia S
PLoS One; 2020; 15(7):e0235038. PubMed ID: 32609729
[TBL] [Abstract][Full Text] [Related]
38. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
39. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive functional assessment of MLH1 variants of unknown significance.
Borràs E; Pineda M; Brieger A; Hinrichsen I; Gómez C; Navarro M; Balmaña J; Ramón y Cajal T; Torres A; Brunet J; Blanco I; Plotz G; Lázaro C; Capellá G
Hum Mutat; 2012 Nov; 33(11):1576-88. PubMed ID: 22736432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
